Subpart G—Specific Labeling Requirements for Specific Drug Products

1. CFR
2. ›
3. Title 21
4. ›
5. Chapter I
6. ›
7. Part 201
8. ›
9. Subpart G

Sections

Section numbering in the official eCFR can be non-consecutive. Omitted section numbers are not treated here as reserved unless the source explicitly labels them that way.

• 201.300
  § 201.300 Notice to manufacturers, packers, and distributors of glandular preparations.
• 201.301
  § 201.301 Notice to manufacturers, packers, and distributors of estrogenic hormone preparations.
• 201.302
  § 201.302 Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil.
• 201.303
  § 201.303 Labeling of drug preparations containing significant proportions of wintergreen oil.
• 201.304
  § 201.304 Tannic acid and barium enema preparations.
• 201.305
  § 201.305 Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings.
• 201.306
  § 201.306 Potassium salt preparations intended for oral ingestion by man.
• 201.307
  § 201.307 Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale.
• 201.308
  § 201.308 Ipecac syrup; warnings and directions for use for over-the-counter sale.
• 201.309
  § 201.309 Acetophenetidin (phenacetin)-containing preparations; necessary warning statement.
• 201.310
  § 201.310 Phenindione; labeling of drug preparations intended for use by man.
• 201.311
  § 201.311 [Reserved]
• 201.312
  § 201.312 Magnesium sulfate heptahydrate; label declaration on drug products.
• 201.313
  § 201.313 Estradiol labeling.
• 201.314
  § 201.314 Labeling of drug preparations containing salicylates.
• 201.315
  § 201.315 Over-the-counter drugs for minor sore throats; suggested warning.
• 201.316
  § 201.316 Drugs with thyroid hormone activity for human use; required warning.
• 201.317
  § 201.317 Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning.
• 201.319
  § 201.319 Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions.
• 201.320
  § 201.320 Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances.
• 201.323
  § 201.323 Aluminum in large and small volume parenterals used in total parenteral nutrition.
• 201.325
  § 201.325 Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required warnings and labeling information.
• 201.326
  § 201.326 Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.
• 201.327
  § 201.327 Over-the-counter sunscreen drug products; required labeling based on effectiveness testing.
• 201.328
  § 201.328 Labeling of medical gas containers.